AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28923239
Drug: PA101 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PA101 (40 mg)
Trial: 25316328
Drug: Paracetamol with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol with NAC administration
Trial: 24090377
Drug: Serum phosphorus
RxNorm normalized name: Phosphorus
DrugBank: Phosphorus (DB14151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum phosphorus above 5.5 mg/dL
Trial: 19508679
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg rhTSH
Trial: 18803554
Drug: 0.005 mg
RxNorm normalized name: biotin 0.005 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.005 mg rhTSH
Trial: 17134956
Drug: Rosuvastatin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin therapy (10mg daily) with a low-fat diet
Trial: 11692298
Drug: Intranasal zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal zinc gluconate
Trial: 30993861
Drug: ipragliflozin 50
RxNorm normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ipragliflozin 50 mg daily
Trial: 31078831
Drug: Probiotic supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplements (Winclove's Ecologic® Barrier), consumed daily over eight weeks
Trial: 31078831
Drug: Placebo, consumed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, consumed daily over eight weeks
Trial: 25052347
Drug: Fecal calprotectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal calprotectin (FC) monitoring after stopping TNFα-blocking therapy
Trial: 24059585
Drug: Overall smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall smoking cessation outcomes in L phase
Trial: 20236148
Drug: TME with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TME with radiosensitizing chemotherapy
Trial: 17377092
Drug: Laser-assisted drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser-assisted drug delivery at 2.0 J/cm2
Trial: 17377092
Drug: Laser-assisted drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser-assisted drug delivery at 3.5 J/cm2
Trial: 14742768
Drug: β-blockers as
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β-blockers as secondary prevention of MI
Trial: 14742768
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose β-blockers with slow titration
Trial: 14742768
Drug: β-blockers in
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β-blockers in post-MI diabetic patients
Trial: 14742768
Drug: Lower oral
RxNorm normalized name: melatonin/val/chamomile flower ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower oral starting doses of β-blockers
Trial: 14742768
Drug: Cardioselective β-blockers
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cardioselective β-blockers and albuterol
Trial: 14742768
Drug: β-blockers in
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β-blockers in patients with peripheral arterial disease
Trial: 19413903
Drug: Stent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stent treatment for coronary disease
Trial: 24411083
Drug: Finasteride 1
RxNorm normalized name: finasteride 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride 1 mg/d
Trial: 3587722
Drug: Thyrotropin Releasing
RxNorm normalized name: Thyrotropin releasing factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyrotropin Releasing Hormone (TRH)
Trial: 30380162
Drug: Anti-hepatitis B
RxNorm normalized name: Anti-Hepatitis Be virus IgG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-hepatitis B virus core antibody (anti-HBc)
Trial: 29105635
Drug: Unani medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unani medicine Renax
Trial: 29105635
Drug: Allopathic medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopathic medicine (Spironolactone + Furosemide)
Trial: 23658070
Drug: Venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine XR treatment
Trial: 21185559
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate mouth wash second hourly (Group B)
Trial: 21185559
Drug: Chlorhexidine 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine 0.2% aqueous oral rinse and second hourly irrigations with sterile water (Group C)
Trial: 21185559
Drug: Sterile water
RxNorm normalized name: sterile water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile water oral rinse second hourly (Group A)
Trial: 17304660
Drug: Etoricoxib 90
RxNorm normalized name: etoricoxib 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 90 mg qd
Trial: 2244403
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium 50 mg tid
Trial: 11214952
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (depot leuprolide 3.75 mg)
Trial: 1336675
Drug: Sumatriptan (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan (3 mg)
Trial: 6348714
Drug: Flurbiprofen 25
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 25 mg
Trial: 27588943
Drug: 2-L PEG
RxNorm normalized name: Iron(2+) L-ascorbate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-L PEG and Ascorbic Acid (Asc)
Trial: 27588943
Drug: 1-L PEG,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-L PEG, Ascorbic Acid (Asc) and 20 mg Bisacodyl (Bis)
Trial: 23312487
Drug: Isoflavone vaginal
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone vaginal gel 4% (1g/day)
Trial: 17112001
Drug: Cisplatin monotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin monotherapy
Trial: 10722763
Drug: Intravenous montelukast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous montelukast (7 mg)
Trial: 10722763
Drug: Oral montelukast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral montelukast (10 mg)
Trial: 8623957
Drug: Desflurane with
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desflurane with ondansetron (4 mg IV)
Trial: 1564466
Drug: Indomethacin 75
RxNorm normalized name: indomethacin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 75 mg daily for 4 weeks
Trial: 1564466
Drug: Usual postoperative
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usual postoperative analgesic treatment (diclofenac sodium twice daily for 5-10 days)
Trial: 25962813
Drug: Transforaminal steroid
RxNorm normalized name: transforming growth factor beta 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transforaminal steroid injection
Trial: 25962813
Drug: Caudal steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal steroid injection
Trial: 23828834
Drug: Modified Constraint-induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Constraint-induced aphasia therapy (CIAT), 3 hours per day for a total of 30 hours of treatment.
Trial: 23828834
Drug: Conventional aphasia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional aphasia therapy, 3 hours per day for a total of 30 hours of treatment.
Trial: 22315331
Drug: sugammadex 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugammadex 4 mg kg(‐1)
Trial: 22315331
Drug: neostigmine 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neostigmine 50 μg kg(‐1)/glycopyrrolate 10 μg kg(‐1)
Trial: 18043345
Drug: Contrast material
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast material with iodine concentration of 370 mg/mL (Group B)
Trial: 18043345
Drug: Contrast material
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast material with iodine concentration of 300 mg/mL (Group A)
Trial: 3235833
Drug: Diuretics (hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics (hydrochlorothiazide and triamterene)
Trial: 3235833
Drug: Diuretics (hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics (hydrochlorothiazide and triamterene) + methyldopa
Trial: 3235833
Drug: Diuretics (hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics (hydrochlorothiazide and triamterene) + methyldopa (considering all cardiovascular events)
Trial: 2144420
Drug: Triglycerides (1.68/0.72
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triglycerides (1.68/0.72 g)
Trial: 2144420
Drug: Free fatty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free fatty acids (1.35/1.065 g)
Trial: 2144420
Drug: Ethyl esters
RxNorm normalized name: SHEA BUTTER ETHYL ESTERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethyl esters (1.86/1.27 g)
Trial: 788738
Drug: Inhaled salmefamol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salmefamol, 100 mug and 200 mug
Trial: 788738
Drug: Inhaled salbutamol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol, 200 mug
Trial: 30963410
Drug: Selenium supplementation
RxNorm normalized name: Selenium supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplementation (200 μg/day for 8 weeks)
Trial: 25826644
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg (0.04 mL of 25 mg/mL) subconjunctival bevacizumab
Trial: 25826644
Drug: 0.04 mL
RxNorm normalized name: ethanol 0.04 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.04 mL of balanced salt solution
Trial: 15197019
Drug: Care manager
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Care manager offered education, problem-solving treatment, or support for antidepressant management
Trial: 9224457
Drug: Heparin‐surface modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin‐surface modified PMMA IOLs
Trial: 8357782
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of quinapril once daily
Trial: 3122717
Drug: Astemizole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole (30 mg daily for 1 week)
Trial: 30030321
Drug: Oral Nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Nutritional Supplement (ONS) intervention
Trial: 22811447
Drug: Ten weeks
RxNorm normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ten weeks of home-based occupational therapy according to the Dutch guidelines of occupational therapy in Parkinson's disease
Trial: 22811447
Drug: No occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No occupational therapy
Trial: 18982536
Drug: Medium-nicotine cigarettes
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medium-nicotine cigarettes (0.6 mg nicotine)
Trial: 18982536
Drug: Low/zero-nicotine cigarettes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low/zero-nicotine cigarettes (0.05 mg nicotine)
Trial: 16567056
Drug: Nicotine Replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Replacement Therapy (NRT) advertising
Trial: 16567056
Drug: Non-pharmaceutical cessation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-pharmaceutical cessation services (Quitline) ads
Trial: 8084247
Drug: Nalbuphine 10
RxNorm normalized name: nalbuphine 10 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 10 mg endovenously every 4 h for the first 12 h and every 6 h for the next 12 h
Trial: 8084247
Drug: Nalbuphine 20
RxNorm normalized name: nalbuphine 20 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 20 mg endovenously every 4 h for the first 12 h and every 6 h for the next 12 h
Trial: 31342247
Drug: Ureteral access
RxNorm normalized name: Bos taurus ureter preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ureteral access sheath (UAS) used for stone treatment (group-1)
Trial: 30709839
Drug: 10 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g/day ground flaxseed for 6 weeks
Trial: 21720788
Drug: P and
RxNorm normalized name: P and S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P and E2 (4 mg/d)
Trial: 16805685
Drug: Er:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG laser treatment at 160 mJ/pulse at 10 Hz
Trial: 8970278
Drug: 10-week behavioral
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10-week behavioral medicine support group intervention
Trial: 1457626
Drug: Melatonin (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (8 mg)
Trial: 6500760
Drug: Mepindolol 10
RxNorm normalized name: mepindolol
DrugBank: Mepindolol (DB13530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepindolol 10 mg at 8 a.m.
Trial: 6500760
Drug: Mepindolol 10
RxNorm normalized name: mepindolol
DrugBank: Mepindolol (DB13530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepindolol 10 mg at 8 p.m.
Trial: 31010875
Drug: Exenatide 2
RxNorm normalized name: exenatide 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide 2 mg once-weekly
Trial: 30033542
Drug: Doxycycline oral
RxNorm normalized name: doxycycline Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline oral capsules 40 mg (DFD-09) under fed conditions
Trial: 30033542
Drug: Doxycycline oral
RxNorm normalized name: doxycycline Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline oral capsules 40 mg (DFD-09) under fasting conditions
Trial: 30033542
Drug: Doxycycline oral
RxNorm normalized name: doxycycline Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline oral capsules 40 mg (DFD-09)
Trial: 12411221
Drug: Transdermal selegiline
RxNorm normalized name: selegiline Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal selegiline (20 mg applied once daily by means of a 20-cm² patch)
Trial: 10636157
Drug: Transdermal selegiline
RxNorm normalized name: selegiline Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal selegiline
Trial: 10449891
Drug: Valsartan in
RxNorm normalized name: Product containing valsartan in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan in combination with ACE inhibitors and other prescribed therapies
Trial: 6758224
Drug: Fansidar (two-tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fansidar (two-tablet regimen)
Trial: 6758224
Drug: Fansidar (three-tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fansidar (three-tablet regimen)
Trial: 17852631
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids (betamethasone-dipropionate cream)
Trial: 7502226
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy (platinum-based combination chemotherapy)
Trial: 2278549
Drug: Ayurvedic drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayurvedic drug treatments for three months
Trial: 28276148
Drug: Follicle flushing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follicle flushing three times with 2 ml in each follicle
Trial: 24841733
Drug: Intralesional tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional tetracycline 2% injection
Trial: 17196795
Drug: SSRIs with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRIs with hormonal therapy (HT)
Trial: 17196795
Drug: SSRIs without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SSRIs without hormonal therapy (HT)
Trial: 11227936
Drug: Rectal pressure-volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal pressure-volume measurement with a compliant balloon
Trial: 11227936
Drug: Rectal impedance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal impedance planimetry
Trial: 9781630
Drug: ACTH infusion
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH infusion (0.25 mg Cosyntropin intravenously over 240 minutes) after hypoglycemic insulin clamp (1 mU/kg/min)
Trial: 9781630
Drug: ACTH infusion
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH infusion (0.25 mg Cosyntropin intravenously over 240 minutes) after euglycemic clamp
Trial: 30526281
Drug: Antithrombotic drug
RxNorm normalized name: Heparin group antithrombotic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic drug use (either antiplatelets or anticoagulants)
Trial: 30526281
Drug: Delay in
RxNorm normalized name: Delayed Release Oral Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delay in surgery after cessation of antiplatelet drug
Trial: 26165370
Drug: Non-specific skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-specific skin points treatment (Control)
Trial: 17214754
Drug: Range-of-motion exercise
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Range-of-motion exercise programme (4-week, twice-per-day, 6 days-per-week) supervised by a Registered Nurse
Trial: 17214754
Drug: Range-of-motion exercise
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Range-of-motion exercise programme (4-week, twice-per-day, 6 days-per-week) with physical assistance from a Registered Nurse
Trial: 11704162
Drug: Venlafaxine (50-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (50-200 mg/day)
Trial: 9791141
Drug: Triple-drug therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-drug therapy (indinavir, zidovudine, lamivudine)
Trial: 2756516
Drug: Nifuroxazide 400
RxNorm normalized name: nifuroxazide 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifuroxazide 400 mg twice a day
Trial: 2756516
Drug: Nifuroxazide 1200
RxNorm normalized name: nifuroxazide
DrugBank: Nifuroxazide (DB13855)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifuroxazide 1200 mg once a day
Trial: 18996523
Drug: ABT-335 +
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-335 + rosuvastatin 10 mg
Trial: 18996523
Drug: ABT-335 +
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-335 + rosuvastatin 20 mg
Trial: 17026664
Drug: Antioxidant preparation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant preparation applied to forearm skin
Trial: 17026664
Drug: Control area
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control area (no antioxidant preparation)
Trial: 15576014
Drug: Sustained-release lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release lithium carbonate matrix tablets containing 450 mg LC with 15% CP
Trial: 15576014
Drug: Sustained-release commercial
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained-release commercial tablet (Eskalith CR)
Trial: 11094787
Drug: 5 mg/m3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/m3 zinc oxide inhalation for naive subjects on 1 or 3 days
Trial: 11094787
Drug: Zinc oxide
RxNorm normalized name: Zinc Oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc oxide inhalation for sheet metal workers on 1 day
Trial: 11094787
Drug: Control furnace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control furnace gas inhalation for sheet metal workers on another day
Trial: 9125668
Drug: Diltiazem extended-release
RxNorm normalized name: diltiazem Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem extended-release 240 mg once daily for 8 weeks
Trial: 8385161
Drug: OPC-21268 10
RxNorm normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC-21268 10 mg
Trial: 8385161
Drug: OPC-21268 50
RxNorm normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC-21268 50 mg
Trial: 8385161
Drug: OPC-21268 300
RxNorm normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC-21268 300 mg, 3 times daily for 7 days
Trial: 8385161
Drug: OPC-21268 100
RxNorm normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC-21268 100 mg single doses
Trial: 3898834
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Sucralfate + Cimetidine)